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Abstract
Background: Invasiveness and metastasis are the most common characteristics of non small cell lung cancer
(NSCLC) and causes of tumour-related morbidity and mortality. Mitogen-activated protein kinases (MAPKs)
signalling pathways have been shown to play critical roles in tumorigenesis. However, the precise pathological role
(s) of mitogen-activated protein kinase phosphatase-1 (MKP-1) in different cancers has been controversial such that
the up-regulation of MKP-1 in different cancers does not always correlate to a better prognosis. In this study, we
showed that the induction of MKP-1 lead to a significant retardation of proliferation and metastasis in NSCLC cells.
We also established that rosiglitazone (a PPARg agonist) elevated MKP-1 expression level in NSCLC cells and
inhibited tumour metastasis.
Methods: Both wildtype and dominant negative forms of MKP-1 were constitutively expressed in NSCLC cell line
H441GL. The migration and invasion abilities of these cells were examined in vitro. MKP-1 modulating agents such
as rosiglitazone and triptolide were used to demonstrate MKP-1’s role in tumorigenesis. Bioluminescent imaging
was utilized to study tumorigenesis of MKP-1 over-expressing H441GL cells and anti-metastatic effect of
rosiglitazone.
Results: Over-expression of MKP-1 reduced NSCLC cell proliferation rate as well as cell invasive and migratory
abilities, evident by the reduced expression levels of MMP-2 and CXCR4. Mice inoculated with MKP-1 over-
expressing H441 cells did not develop NSCLC while their control wildtype H441 inoculated littermates developed
NSCLC and bone metastasis. Pharmacologically, rosiglitazone, a peroxisome proliferator activated receptor-g (PPARg)
agonist appeared to induce MKP-1 expression while reduce MMP-2 and CXCR4 expression. H441GL-inoculated
mice receiving daily oral rosiglitazone treatment demonstrated a significant inhibition of bone metastasis when
compared to mice receiving sham treatment. We found that rosiglitazone treatment impeded the ability of cell
migration and invasion in vitro. Cells pre-treated with triptolide (a MKP-1 inhibitor), reversed rosiglitazone-mediated
cell invasion and migration.
Conclusion: The induction of MKP-1 could significantly suppress the proliferative and metastatic abilities of NSCLC
both in vitro and in vivo. Therefore, MKP-1 could be considered as a potential therapeutic target in NSCLC therapy
and PPARg agonists could be explored for combined chemotherapy.
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Background
Lung cancer represents the leading cause of cancer-
related deaths in many countries. It is estimated that
there are 0.2 million diagnosed cases of lung cancer and
over 0.16 million patients die from it in the United
States alone [1]. The most common type of lung cancer
is non-small cell lung cancer (NSCLC) which contri-
butes to over 75% of all cases [2]. Despite advances in
therapeutic strategies, less than 15% of patients with
NSCLC survive beyond 5 years of initial diagnosis. The
precise etiology of NSCLC is complex. However, activat-
ing mutations of the KRAS protooncogene and/or EGFR
are believed to play a major role in NSCLC tumorigen-
esis [3,4]. KRAS and EGFR mutations lead to overt
activities of their downstream pro-survival and anti-
apoptotic signaling pathways, attributing not only to the
development of lung cancer but also a positive correla-
tion to poor prognosis and response to conventional
therapies [5]. Due to the extensive contributions from
lateral signaling molecules and pathways, the therapeutic
efficacies of KRAS and EGFR targeted therapies have
been disappointing thus new regimens are required.
The mitogen-activated protein kinases (MAPKs)
represent the common downstream effectors of EGFR
and KRAS; the dynamic balance between MAPKs and
their respective phosphatases (MKPs) ultimately deter-
mine whether cells undergo survival or apoptosis [6]. In
particular, MKP-1, the prototype member of dual-speci-
ficity MAPK phosphatases, has been shown to play
either pro-or anti-apoptotic role depending on the cell
types. For instance, the over-expression of MKP-1 has
been detected in breast cancer and associated to its
malignancy [7]. On the contrary, decreased level of
MKP-1 was found in association with high histological
grade of prostate, colon and bladder cancer and distant
metastasis [8]. In advanced epithelial ovarian cancer,
this phosphatase was found down-regulated and its re-
expression reduced the malignant potential of neo-
plasms [9]. Thus far, the role of MKP-1 in lung cancer
has not been clearly illustrated. However, a previous
study demonstrated an increased level of MKP-1 was
accompanied with MAPKs in NSCLC lung specimens as
compared to normal lung [10]. In the same report, the
authors suggested that high MKP-1 expression levels
independently predicted improved patients’ survival. For
these reasons, therapeutic strategies that employ MKP-1
induction for the suppression of tumor proliferation and
metastasis could be of clinical importance. Several stu-
dies have demonstrated that PPARg agonist, thiazolidi-
nedione, a class of anti-diabetic drugs including
rosiglitazone and troglitazone, significantly inhibit pri-
mary tumor growth and metastasis in a variety of can-
cers including colon, breast, prostate, brain and lung
[11-15]. However, the mechanisms by which these
PPARg agonists suppress NSCLC cell tumorigenesis
have not been elucidated fully. Based on these premises,
we sought to explore the precise pharmacological role(s)
of MKP-1 in the development and progression of
NSCLC and the possible involvement of MKP-1 in rosi-
glitazone-mediated tumor suppression. To achieve our
goals, we over-expressed either wildtype or dominant
negative forms of MKP-1 in a NSCLC cell line, H441GL
which contains dual reporter genes, enhanced green
fluorescence protein (G) and firefly luciferase (L), to
assess its impact both in vitro and in vivo, as well as the
pharmacological induction of MKP-1 by rosiglitazone.
Methods
Reagents and Antibodies
Trizol regent, glutamine, gentamycin penicillin, and
streptomycin were purchased from Life Technologies
(Gaithersburg, MD) and all antibodies specific for
MMP-2, MKP-1, phospho-p38, phospho-ERK, phospho-
JNK, CXCR4 and a-tubulin were all purchased from
Santa Cruz Biotechnologies (Santa Cruz, CA). Horserad-
ish peroxidase-conjugated anti-rabbit IgG secondary
antibody was purchased from Bio-Rad (Hercules, CA).
Rosiglitazone powder was obtained from Dr. Wang CY
from Far Eastern Memorial Hospital (supplied by GSK
Taiwan branch) while rosiglitazone tablets, Avandia® (4
mg) were purchased from Taipei Medical University
Hospital Pharmacy. Dimethyl sulfoxide (DMSO) was
used to dissolve both rosiglitazone powder and tables.
Constructs, Cells and Culture Conditions
Non-small cell lung cancer (NSCLC) NCI-H441GL cells
expressing dual reporters, enhanced green fluorescent
protein (G) and firefly luciferase (L) were generously
provided by Dr. Juri Gelovani at University of Texas,
MD Anderson Cancer Center, Texas Houston, USA.
Cells were grown in RPMI medium supplemented with
10% FBS, containing 2 mM glutamine and antibiotics
(100 U/ml penicillin and 100 μg/ml streptomycin). After
reaching 80% confluence, cells were treated with various
concentrations of rosiglitazone and various inhibitors of
MAPKs (30 μM, unless indicated) and incubated for
24 h (unless specified) in a 5% CO2 humidified incuba-
tor at 37°C. During rosiglitazone (0-30 μM) treatment,
serum free medium was used in order to synchronize
the cells and eliminate possible interference from serum.
Both wildtype and dominant negative MKP-1 full length
cDNAs were PCR-amplified with primers containing
BamHI and EcoRI linkers and was inserted into
pcDNA3.1 vector (cat #V79020, Invitrogen, Taipei, Tai-
wan). H441GL cells (CL1-5F4 and A549 cells) were
seeded at 5 × 105 cells in 6-cm plates and were
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transduced with wildtype pcDNA3.1/MKP-1, dominant
mutant pcDNA3.1/MKP-1CS (C258S mutation) and
empty pcDNA3.1 vectors using Lipofectamine 2000
(Invitrogen, Taipei, Taiwan). After recovery, positive
clones were selected using Geneticin (Gibco BRL Life
Technologies, Inc.).
RNA Extraction and Semi-Quantitative PCR Analysis
Total RNA was extracted from cultured cells using TRI-
zol according to manufacturer’s protocols. Reverse tran-
scription reactions were carried out to obtain cDNA
according to standard protocols. Primer sequences are
listed as follows (forward primer is listed first followed
by the reverse primer). MKP-1 5’-GCTGTGCAGCAAA-
CAGTCGA-3’ and 5’-CGATTAGTCCTCATAAGGTA-








and 5’-CATGCCAGTGAG CTTCCCGT-3’; All primers
were derived from human cDNA sequences, and PCR
conditions were optimized so that the gene products
were in the exponential phase of amplification (94°C for
2 min followed by 30 (30 sec) cycles at 94°C, 55°C for 1
min, and 72°C for 1 min; followed by a 7-min final elon-
gation at 72°C). PCR products were resolved on 1.5% 2%
agarose gels containing 1 μg/ml ethidium bromide and
visualized/analyzed using FloGel-I (Fluorescent Gel
Image System; TOP BIO Co.)
Polyacrylamide gel electrophoresis and Western blotting
Cell lysates were separated by SDS-PAGE and trans-
ferred onto PVDF membranes for immunoblotting.
Membranes were subject to blocking solution (1×PBS,
containing 3% BSA and 0.1% Tween 20) for 1 h at room
temperature followed by the incubation of respective
primary and secondary antibodies. Immunodetection
was carried out by LumiGLO chemiluminescence kit
(Amersham, UK).
Gelatin zymography
Equal numbers of cells (1 × 106) were seeded onto 100-
mm dishes and cultured with serum free medium for 24
h. Equal amount of media were collected and MMP-2
activities were determined by gelatin zymography with
0.1% gelatin as a substrate in a 10% SDS-polyacrylamide
gel. After the addition of 2× sample buffer, cell media
were directly loaded on to gels. Samples were renatured
by exchanging SDS with 2.5% Triton X-100. The gel
was incubated at 37°C in developing buffer containing
50 mM Tris-HCl, (pH 7.6) and10 mM CaCl2. Gel was
then stained with 0.25% Coomassie blue R250, 40%
methanol, and 10% acetic acid at room temperature and
destained with 40% methanol, 10% acetic acid until the
bands of lysis became clear. The MMP-2-relative
photographic density was quantitated by scanning the
photographic negatives on a gel analysis system (BioS-
pectrumAC Imaging System Vision with LS software,
UVP Inc., Upland, California, USA).
In Vitro Invasion Assay
Matrigel invasion assays were performed with a Boyden-
chamber assay using BD BioCoat Matrigel Invasion
Chambers (BD Biosciences, San Jose, CA). To determine
the invasiveness, H441GL, H441GL/MKP-1 and
H441GL/MKP-1CS cells were seeded in the upper com-
partment of each chamber (1 × 105cells/well, serum-free
DMEM) while the lower compartments were filled with
DMEM containing 10% FCS. Non-invading cells were
gently removed after 24 h. Cells on the bottom side of
the filter were fixed, stained, and counted under a light
microscope (×200 magnification). All experiments were
repeated three times.
In Vitro Cell Viability Assay
For dye exclusion assay, cells were seeded at the density
of 2.5 × 104 cells/well, in 24-well plates. The media
were removed, and the cells were rinsed with PBS
before incubation with trypsin. Cells were then washed,
and resuspended in 0.4% trypan blue, and live cells were
counted using a hemocytometer.
In vivo monitoring of NSCLC
SCID (Severe combined immunodeficiency) mice were
maintained in a specific pathogen-free environment in
compliance with institutional policy and all animal proce-
dures were previously approved by the IACUC (Institu-
tional Animal Care and Use Committee) at Taipei
Medical University. Wildtype NSCLC H441GL and
MKP-1 overexpressing H441GL (H441GL/MKP-1) were
intravenously administered into SCID mice via tail vein
at a concentration of 5.5 × 105/100 μl PBS. The growth
and metastasis of tumor cells were monitored in real
time with IVIS 200 imaging system, equipped with Living
Imaging software (Xenogen, Alameda, CA). Rosiglitazone
tablets (Avandia™, 4 mg) was grounded and dissolved in
0.1% DMSO and given to mice bearing H441GL tumor
via daily gavage at a concentration of 10 mg/kg/d.
Statistical Analysis
All data are expressed as the means ± SD for the num-
ber of experiments. Statistical significance (*, p < 0.05;
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**, p < 0.01) between experimental and control groups
was calculated by student T-test.
Results
Induction of MKP-1 Reduces Cell Proliferation Rate and
Initiates Mesenchymal-to-Epithelial Switch in NSCLC Cells
To examine the role of MKP-1 in the development and
progression of NSCLC, H441GL cells were selected for
transient over-expression of both wildtype (H441GL/
MKP-1) and non-functional MKP-1 (H441GL/MKP-
1CS). Both transcriptional and translational levels of
mkp-1 in H441GL cells were significantly up-regulated
(Figure 1A and 1B), indicating a successful expression of
mkp-1 gene. Next, we examined all three major players
involved in MAPK signal transduction pathway, namely
p38, ERK1/2 and JNK. An increased level of wildtype
MKP-1 resulted in a decreased level of phospohorylated
p38 and ERK1/2 and JNK to a much less extent. Con-
versely, over-expression of non-functional MKP-1 had
no effect on the 3 members of MAKP pathway (Figure
1B, all see Additional file 1). Because MAPKs are major
cell cycle regulators, cellular proliferation rates of
H441GL/MKP-1 (wildtype) and H441GL/MKP-1CS
(dominant negative mutant) were examined and com-
pared. H441GL/MKP-1 cells exhibited a marked reduc-
tion in proliferation rate when compared to its mutant
and mock-transfected counterparts (Figure 1C). Simi-
larly, MKP-1 over-expression also led to a reduction in
cell viability in other NSCLC cell lines namely CL1-5 F4
and A549 cells (see Additional file 2).
An increase in MKP-1 protein expression also initiated a
mesenchymal-to-epithelial switch in H441GL cells. A
decrease in vimentin transcript was accompanied by a
slight increase in E-cadherin transcript, in MKP-1 over-
expressing H441GL cells (Figure 1D).
Induction of MKP-1 Down-regulates MMP-2 and CXCR4
Expression in NSCLC H441GL Cells
The ability of tumour cells to invade and migrate has
been ascribed to the up-regulation of matrix metallopro-
teases (MMPs) and chemotactic axis CXCR4/SDF-1
[16]. In addition, MAPKs activities have been linked to
the regulation of MMPs and CXCR4 [17,18]. Initially,
we established that inhibition of MAPKs led to the
down-regulation of MMP-2 and CXCR4. As depicted in
Figure 2A, H441GL cells treated with SB203580 (a p38
MAPK inhibitor), PD98059 (an ERK inhibitor), or
SP600125 (a JNK inhibitor), showed reduced expression
levels of MMP-2 and CXCR4 when compared to control
cells. Similarly, the inhibition of p38 MAPK, ERK and
JNK led to a reduced MMP-2 enzymatic activity in
H441GL cells (Figure 2B). It appeared that MMP-2
enzymatic activity was hampered to a larger extent
when p38 MAPK and ERK were inhibited. Next, we
demonstrated that MKP-1 over-expression directly
resulted in a suppressed enzymatic activity of MMP-2
(Figure 2D) and was accompanied with a lower expres-
sion level of MMP-2 and CXCR4 (Figure 2C) in
H441GL cells. The catalytically inactive mutant of
MKP-1 (H441GL/MKP-1CS) did not affect MMP-2 and
CXCR4 expressions.
Increased MKP-1 Expression Reduces Invasive and
Migratory Abilities of H441GL Cells
We established that MAPK pathways were responsible
for regulating the expression levels of MMP-2 and
CXCR4, concomitantly MKP-1 expression was nega-
tively correlated to the expression and activity of both
gene products. It was then our goal to demonstrate that
MAPKs and MKP-1 regulated cellular invasiveness and
migration via MMP-2 and CXCR4. H441GL cells treated
with MAPK pathway inhibitors, SB203580, PD98059,
and SP600125, exhibited a reduced level of invasiveness
(Figure 3A) and migration (Figure 3B) in H441GL cells.
It appeared that both cellular invasiveness and migration
were hampered to a greater extent in H441GL cells
when p38 MAPK and ERK were both inhibited (Figure
3A and 3B). Subsequently, H441GL cells were trans-
duced with MKP-1 and examined its roles in cellular
invasiveness and migration. It was observed that both
invasive and migratory (Figures 3C and 3D, respectively)
abilities of MKP-1 over-expressing H441GL cells were
severely affected. These observations were in agreement
with the reduced expression levels of MMP-2 and
CXCR4 as the result of an increase in MKP-1 expres-
sion. Similarly, when MKP-1 expression level was ele-
vated in A549 and CL1-5F4 (a highly invasive lung
adenocarcinoma cell line) cells, their invasiveness was
also significantly reduced (see Additional file 3).
Pharmacologically-induced MKP-1 Expression Leads to
the inhibition of Invasion and Migration of H441GL cells
In Vitro
Rosiglitazone (RGZ), a PPARg agonist used in type 2
diabetes treatment, has been shown to reduce the malig-
nancy in variety of cancers [12]. In rosiglitazone-treated
HUVECs cells, the expression and activity of ERK1/2
and p38 MAPK were significantly down-regulated [19].
To this end, we set out to determine whether rosiglita-
zone is a pharmacological inducer of MKP-1 in NSCLC
model. In NSCLC, rosiglitazone treatment was found to
increase the expression of MKP-1 in H441GL cells in a
dose-dependent manner (Figure 4A). This dose-depen-
dent rosiglitazone-mediated up-regulation of MKP-1
expression was accompanied by a reduction in MMP-2
and CXCR4 expression level (Figure 4A) and activity
(Figure 4C). When MKP-1 was inhibited by a pharma-
cological inhibitor, triptolide (Trp), rosiglitazone-
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mediated down-regulation of MMP-2 and CXCR4 was
hampered as the result of diminished level of MKP-1
(Figure 4B and 4D). Next, a matrigel-coated chamber
system was used to investigate the effects of rosiglita-
zone on H441GL invasiveness and migration. Rosiglita-
zone posed an inhibitory effect on both invasive (Figure
4E left panel) and migratory (Figure 4E right panel) abil-
ities of H441GL cells (see Additional file 4). The highest
concentration of rosiglitazone (30 μM) reduced H441GL
cells’ invasive and migratory abilities by approximately
60% and 40%, respectively. When triptolide was added
rosiglitazone-mediated reduction in invasion and migra-
tion was reversed (Figure 4F, left and right panels,
respectively).
Elevated MKP-1 Expression, Intrinsic or
Pharmacologically-induced, Inhibits NSCLC Metastasis in
Mice
The physiological roles of MKP-1 in NSCLC tumorigen-
esis and metastasis were further explored in vivo,
assisted by non-invasive molecular imaging system.
Mice, inoculated with wildtype H441GL cells, developed
Figure 1 In Vitro Characterizations of MKP-1 over-expressing H441GL NSCLC Cells (A) In vitro validation of MKP-1 over-expression in
H441GL cells at transcriptional level. Both dominant negative (H441GL/MKP-1CS) and wildtype MKP-1 (H441GL/MKP-1) constructs were
transduced into H441GL cells Strong MKP-1 transcripts were visualized by ethidium bromide stain Empty vector pcDNA31 served as a control
and demonstrated no increased amount of MKP-1 transcript in the tranduced host GAPDH served as a loading control (B) Immunoblots showing
MKP-1 over-expression reduced MAPK activities H441GL cell lysates were immunoblotted with antibodies specific for MKP-1, phosphorylated
p38MAPK, ERK, JNK or a-tubulin Phosphorylated MAPKs including p38MAKP, ERK and JNK activities were down-regulated by wildtype MKP-1
over-expression (C) Cellular proliferation was examined in MKP-1 over-expressing H441GL cells using dye exclusion assay H441GL cells
transduced with dominant negative MKP-1 (H441/MKP-1CS) and empty vector (H441GL/pcDNA31) exhibited similar proliferation rate whereas
wildtype MKP-1 over-expressing H441GL cells (H441GL/MKP-1) demonstrated markedly reduced proliferation rate Data was shown as mean ± SD
of three independent experiments (D) Induction of MKP-1 triggered mesenchymal-to-epithelial status switch in H441GL cells by increasing E-
cadherin (E-cad) while decreasing Vimentin expression Internal controls used in PCR and Western analyses were GAPDH and a-tubulin
respectively.
Tai et al. BMC Cancer 2010, 10:95
http://www.biomedcentral.com/1471-2407/10/95
Page 5 of 14
large tumour burden and signs of distant metastasis
within a week. By week 2, most mice showed severe
lung-bone metastasis (Figure 5A, left panels). In con-
trast, animals received MKP-1 over-expressing H441GL
cells did not even develop tumour burden and remained
tumour-free after two weeks (Figure 5A, middle panels,
also see Additional file 5). In parallel, we examined
whether rosiglitazone’s in vitro anti-proliferative and
anti-metastatic effects could be replicated in H441GL-
inoculated mice by oral gavage treatment. Mice receiv-
ing daily oral of gavage rosiglitazone, developed tumour
burden one week post-inoculation (Figure 5A, right
panels). However, lung-bone metastasis appeared to be
significantly delayed in the rosiglitazone-treated animals.
The first incidence of metastasis was not observed until
week 2 and most animals remained metastasis-free. The
rate of metastasis was tabulated based on our optical
imaging analysis. As indicated in Figure 5B, MKP-1
over-expressing group exhibited the lowest metastasis
rate (12.5%), followed by rosiglitazone-treated group
(25%) and control group (62.5%). The survival rate of
these animals was recorded and represented by a
Kaplan-Meier plot after one month of inoculation (Fig-
ure 5C). Mice inoculated with H441GL/MKP-1 cells
exhibited the highest survival rate (80%) followed by the
animals receiving rosiglitazone treatment (60%) while
the control animals without any treatment had the low-
est survival rate (25%).
Discussion
Herein, we assessed the functional significance of MKP-
1 in the regulation of tumor proliferation and metastasis
Figure 2 MKP-1 regulates expressions of MMP-2 and CXCR4 in H441GL cell. H441GL cells were treated with a p38MAPK (SB203580), an
ERK1/2 inhibitor (PD98059), or a JNK (SP600125) (all at 30 μM) (A) Cell lysates were immunoblotted with antibodies specific for MMP-2, CXCR4,
or a-tubulin Inhibitors against MAKPs all reduced both CXCR4 and MMP-2 expression levels except inhibitor against JNK did not significantly
reduced MMP-2 expression Corresponding MMP-2 activity was measured using zymography (B). (C) MMP-2 and CXCR4 expression were
examined in MKP-1 over-expressing H441GL cells Decreased expression levels of both molecules were detected in wildtype MKP-1 over-
expressing H441GL cells (H441GL/MKP-1) when compared to those of in vector control (H441GL/pcDNA31) and dominant negative form of MKP-
1 (H441GL/MKP-1CS) Corresponding MMP-2 enzymatic activity was demonstrated by zymography (D).
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using a mouse model assisted by molecular imaging
technology. An increased level of MKP-1 by protein
over-expression significantly slowed the progression of
lesions from premalignant to invasive and impaired the
growth of tumours. Moreover, we provided mechanistic
evidence that MKP-1 suppresses both tumour prolifera-
tion and metastasis via promoting mesenchymal-to-
epithelial transition followed by the dampening of
MMP-2 and CXCR4 activities. As for clinical translation,
rosiglitazone, a widely used anti-diabetic agent was
shown to convey its anti-tumour effects via the induc-
tion of MKP-1.
Mitogen-activated protein kinase dual specificity phos-
phatase-1 (primarily known as MKP-1, DUSP1 or
CL100) is an immediate-early gene whose expression is
under the regulation of various cellular signals [20-22].
MKP-1 negatively regulates its substrates, mitogen-acti-
vated protein kinases (MAPKs) including p38MAPK,
JNK and ERK1/2, via dephosphorylation [23]. MKP-1
expression level has been positively linked to different
types of cancer such as human ovarian carcinoma,
breast and prostate cancer [7,24,25]. However, a nega-
tive correlation between MKP-1 expression and the
prognosis of cancer has also been documented in
Figure 3 MKP-1 regulates invasive and migratory abilities in NSCLC H441GL cells. Cell invasive (A) and migratory (B) abilities of H441GL
cells were examined under the presence of different inhibitors of MAPKs (all at 30 μM) including p38 MAPK (SB203580), ERK1/2 (PD98059), and
JNK (SP600125) inhibitors The degree of inhibition in H441GL invasiveness (C) and migration (D) when MKP-1 was over-expressed was examined
The inhibition of invasiveness and migration was found at the following order, p38>ERK>JNK and p38≃ERK>JNK respectively Data represent
mean ± SD (n = 3).
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Figure 4 Rosiglitazone regulates MMP-2 and CXCR4 expression via MKP-1 induction. (A) H441GL cells treated with different concentrations
of rosiglitazone (RGZ, 0 to 30 μM) demonstrated a decrease in both MMP2- and CXCR4 protein expression levels accompanied by an increase
in MKP-1 expression level in a dose-dependent fashion This effect was reversed when triptolide (TRP, a MKP-1 inhibitor at 10 ng/ml) was added
(B) (C-D) As demonstrated by zymography, MMP-2 enzymatic activity was reduced by RGZ in a dose-dependent manner, and this reduction by
RGZ could be reversed by the addition of triptolide (E-F) Corresponding in vitro invasion and migration assays also showed RGZ treatment
decreased cellular mobility of H441GL cells Data expressed as mean ± SD (n = 3).
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Figure 5 Non-invasive bioluminesence monitoring of NSCLC tumour suppression by either MKP-1 over-expression or rosiglitazone
treatement. (A) Representative bioluminescence images of SCID mice injected with either control H441GL cells (H441GL), MKP-1 over-expressing
H441GL (H441GL/MKP-1) or control H441GL-inoculated mice receiving daily oral rosiglitazone (100 mg/kg/d) treatment (ROSI-H441GL) The
intensity of bioluminescent signals increased in both control and ROSI-treated groups but not the mice inoculated with H441GL/MKP-1, over the
14-day observation period The intensity of bioluminescent signals reflects the increase in tumour burden (B) Metastatic ability was tabulated
based on bioluminescence analysis Control H441GL mice showed the highest lung-to-hind leg metastasis rate (625%) followed by ROSI-H441GL
(25%) and H441GL/MKP-1 animals (125%) (C) Kaplan-Meier plot indicated that H441GL/MKP-1 animals had the best survival rate among the three
groups, ROSI-H441GL group being the modest (60%) and the control H441GL animals the worst (25%) The insert table depicts the percentage of
lung-to-bone metastases obtained from three groups.
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hepatocellular carcinomas [26,27]. In the case of lung
cancer, the role of MKP-1 appears to be controversial as
well. It was shown that a higher MKP-1 expression was
detected in NSCLC versus small cell lung cancer cell
lines. However, there is no definitive correlation
between individual clinicopahtological variables or
MAPK phosphorylation status when examined by
immunohistochemical assay and MKP-1 expression [11].
In order to better define the role of MKP-1 in NSCLC
tumorigenesis, we over-expressed MKP-1 in H441GL
cells. It was found that the increased MKP-1 expression
level significantly retarded both proliferative and meta-
static abilities in these cells both in vitro and in vivo
and these inhibitory effects were attributed to the com-
bined and differential dephosphorylation of three major
MKP-1’s substrates in the decreasing order of prefer-
ence, p38MAPK, ERK1/2 and JNK. The selective hyper-
activation of p38 MAPK signalling in NSCLC (and other
cancer types) has been correlated to malignant transfor-
mation [28,29] via the induction of MMP-2 [30-32] and
CXCR4/SDF-1 chemotaxis axis [33]. In addition, the
deactivation of ERK 1/2 and JNK is associated with cell
cycle arrest [34] and impaired cell migration [35,36]
respectively. Thus, the decreased malignancy of
H441GL/MKP-1 appeared to be logical and supported.
Interestingly, the phosphorylation level of JNK (the
activated form) was not significantly altered in H441GL/
MKP-1 cells. Currently, the underlying mechanism of
this selective MAPK signalling down-regulation in
H441GL/MKP-1 cells remains elusive but it could be
attributed to the preferential up-regulation of p38
MAPK in NSCLC [29] and the comparatively lesser role
of JNK in tumorigenesis to p38 MAPK [37]. As an
added advantage, MKP-1 over-expressing NSCLC cells
displayed a significant reduction in glucose uptake abil-
ity, a reduced Warburg effect (see Additional file 6).
This significantly reduced glucose uptake ability of
H441GL/MKP-1 cells provides a further support to the
observed proliferation suppression both in in vitro and
bioluminescence imaging data where mice inoculated
H441GL/MKP-1 cells did not result in tumorigenesis.
Similarly, rosiglitazone treatment also negatively affected
H441GL cells’ glucose uptake ability although to a lesser
extent when compared to intrinsic elevation of MKP-1
in H441GL/MKP-1 cells. This could partially explain
why oral rosiglitazone treatment was not as effective as
MKP-1 over-expression in tumour suppression.
Peroxisome proliferator-activated receptor-gamma
(PPARg) exerts compounded roles in cell differentiation,
tissue metabolism and host immunity and recently is
implicated in tumor suppression [38]. Of clinical signifi-
cance, a 33% reduction in lung cancer risk in diabetic
patients who received thiazolidinedione class drugs
was observed [39]. However, the role of PPARg in
tumorigenesis have been controversial [40-43] and the
molecular mechanism underlying PPARg-mediated
tumor suppression remains unclear [44,45]. In this
study, we demonstrated that the usage of rosiglitazone
(a PPARg agonist) inhibited NSCLC H441GL cell
growth and metastasis both in vitro and in vivo. Based
on our experimental data, we proposed that rosiglita-
zone-induced tumor suppression is due to a combina-
tion of PPARg-dependent and PPARg-independent
pathways. Suppression of tumor growth is most likely
achieved by the induction of MKP-1 which leads to the
down-regulation of p38MAPK and ERK1/2, a PPARg-
independent event; retardation of metastases is via a
PPARg-dependent pathway which directly decreases
CXCR4 and MMP expressions (Figure 6). We also
found that rosiglitazone treatment resulted in altered
expression levels in other genes using a RNA array sys-
tem. The expression levels of bone morphogenetic pro-
teins 2 and 4 (BMP2 and BMP4), both have been
suggested to play important roles in tumour metastasis,
showed a 10 and 14 fold decrease by rosiglitazone,
respectively. In contrast, rosiglitazone treatment elicited
a 14 fold increase in tumour suppressor gene INK4a
expression (Data not shown).
Important insights were obtained from our H441GL-
inoculated mice using non-invasive bioluminescence
imaging. First, MKP-1 over-expressing H441GL-inocu-
lated animals (H441GL-MKP-1) exhibited a much
higher survival rate when compared to both rosiglita-
zone-treated and sham-treated animals. In fact, biolumi-
nescence imaging data revealed that tumour burden was
reduced significantly in H441GL-MKP-1-inoculated
mice one week post inoculation, indicating that an
increase in MKP-1 expression in H441GL cells pre-
vented tumour growth in vivo. In addition, this observa-
tion established that an intrinsic up-regulation of MKP-
1 represented a powerful tool for tumour suppression
and a potential candidate for target therapy develop-
ment. Second, H441GL-bearing mice receiving rosiglita-
zone (100 mg/kg/d) treatment (Rosi-H441GL) exhibited
similar tumour volume when compared to control
H441GL group but distant (bone) metastasis in Rosi-
H441GL group was significantly inhibited. Our data was
supported by an earlier study demonstrating oral rosigli-
tazone treatment also inhibited metastasis of murine
mammary cancer cells without affecting the tumour size
[46]. However, this finding revealed that the cellular
level of MKP-1 induced by current rosiglitazone treat-
ment might not be sufficient, perhaps due to the differ-
ence between the bioavailability, to mirror our in vitro
observations. Similarly, a recent report indicated that
lung cancer-bearing mice which received lone oral rosi-
glitazone treatment (chow pellet) did not produce as a
significant degree of tumour suppression as compared
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to intraperitoneal injected carboplatin or combined rosi-
glitazone and carboplatin treatments [47].
Conclusion
Treating lung cancer is a notoriously difficult task due
to its high tendency for distant metastasis and resistance
to both chemo- and radiotherapies. Despite the fact that
MKP-1 has been implicated as a negative prognostic
indicator in several cancers including ovarian [26] and
breast [48] carcinomas, there are also incidences where
over-expression of MKP-1 appears to be beneficial as in
hepatocellular [27] and urothelial carcinomas [49]. In
this study, we presented a collection of evidence sup-
porting MKP-1’s role as a tumour suppressor in
NSCLC. An elevated level of MKP-1 protein either by
over-expression or rosiglitazone treatment, resulted in
the suppression of proliferative, migratory and invasive
abilities of H441GL cells. Using molecular imaging tech-
nique, we were able to in vivo monitor H441GL tumour
progression where MKP-1 over-expressing and rosiglita-
zone-treated groups demonstrated significant tumour
growth and metastasis inhibition respectively as com-
pared to the wildtype H441GL inoculated group. As for
pharmacological relevance, we reported that rosiglita-
zone, a widely-used and well-tolerated anti-diabetic
agent, conveys its anti-tumour ability via MKP-1 induc-
tion. Based on these premises, MKP-1 itself could be a
candidate for target therapy and agents capable of
Figure 6 Proposed pharmacological role of MKP-1 in rosiglitazone-mediated tumour suppression. Rosiglitazone exerts its anti-tumour
effects via both PPARg-dependent (via CXCR4) and PPARg-independent (via MKP-1 induction) pathways Two major MAPKs affected by the
induction of MKP-1 are p38 and ERK which participate in the regulation of cellular mobility and proliferation respectively (® direct stimulatory
modification; –> tentative stimulatory modification; –| direct inhibitory modification).
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inducing MKP-1 expression such as rosiglitazone or
other similar compounds should receive considerations
for clinical tests.
Additional file 1: Figure S1. Major MAKP protein expression profiles in
MKP-1 and MKP-1CS over-expressing H441GL cells The total protein
levels of p38MAPK, ERK and JNK were not affected by the over-
expression of MKP-1 as demonstrated by the western blots.
Additional file 2: Figure S2. MKP-1 induction reduces NSCLC viability
Two other NSCLC cell lines CL1-5F4 and A549 over-expressing MKP-1
were also examined for their viability using MTT assay Cells with elevated
MKP-1 expression level, CL1-5F4/MKP-1 and A549/MKP-1 showed a
significantly lower viability when compared to their respective vector-
transduced controls, CL1-5F4/pcDNA31 and A549/pcDNA31 (n = 3).
Additional file 3: Figure S3. MKP-1 over-expression reduces
invasiveness in CL1-5F4 and A549 NSCLC cells Both CL1-5F4 and A549
were also examined for their in vitro invasive ability using matrigel assay
(A) Photographic representations of the cells migrated through the
matrigel system (B) Quantitative analysis of cell invasiveness Both CL1-
5F4/MKP-1 and A549/MKP-1 cells appeared to lose their invasive ability
under the influence of MKP-1 over-expression while the vector controls
remain highly invasive (n = 3).
Additional file 4: Figure S4. Cell viability assay of H441GL cells treated
with various concentrations of rosiglitazone (RGZ) The MTT survival ratio
of H441GL cells were obtained at different RGZ concentrations (ranging
from 0-30 μM). RGZ appeared to have a minor role in affecting cellular
viability because even at 30 μM, the survival ratio was still maintained
approximately at 87%. The slight decrease in the cell viability in RGZ
treated H441GL cells did not contribute to the marked effect of RGZ in
reducing invasiveness and migration in these cells.
Additional file 5: Figure S5. In vivo monitoring of tumorigenesis of
H441GL/MKP-1CS (dominant negative) inoculated mice. Tumorigenesis in
mice inoculated with H441GL cells expressing the dominant negative
form of MKP-1 was observed using non-invasive bioluminescence
imaging. As demonstrated, H441GL/MKP-1CS cells behaved very similarly
to H441GL parental cells.
Additional file 6: Figure S6. Glucose uptake ability is down-regulated
by the induction of MKP-1. Glucose uptake ability was measured and
represented by the percentage of radio-active 3H-glucose incorporated in
different NSCLC cell lines (A) Glucose uptake ability was severely retarded
in all MKP-1 over-expressing cells (MKP-1) when compared with their
respective controls (pcDNA31) (B) Treatment of rosiglitazone (30 μM) also
suppressed glucose uptake ability in ROSI/A549 and ROSI/H441GL cells
but not their respective controls (All experiments were performed in
triplicates). Experimental protocol for glucose uptake assay. Cancer cells
have been known to exhibit enhanced metabolism, as reflected in the
significantly marked glucose uptake ability (Warburg effect). Based on our
finding in this study, MKP-1 over-expressing NSCLC cells showed a
marked reduction in proliferative ability via ERK-mediated pathway. To
further support this notion, we examined the glucose uptake ability of
these MKP-1 over-expressing NSCLC cells. Glucose uptake assay was
performed in triplicate. NSCLC cells were seeded in 12-well plate at a
density of 3 × 105cells/well. Cells were incubated in medium contained
0.1 mM 2-deoxy-D-glucose and 0.5 μCi 2- [1,2-3H]-2-deoxy-D-glucose.
Following incubation for 1 h, samples were washed twice with cold Ca2
+- and Mg2+-free phosphate-buffer saline. Cells were then lyzed in 10
mM Tris-HCl (pH 8.0) containing 0.2% SDS, the incorporated radioactivity
was then determined using TopCount NXT™ Microplate Scintillation and
Luminescence Counter (Perkin Elmer, Taipei, Taiwan).
Abbreviations
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